..................................................................................................................................................................................
RENAL OSTEODYSTROPHY
1. In Memoriam – A tribute to Professor Jack W. Coburn
Fernando Carrera
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 5
2. Foreword: Why a new supplement on renal osteodystrophy?
Fernando Carrera
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 7
3. Renal osteodystrophy with special emphasis on
secondary hyperparathyroidism.
Ewa Lewin, Jinxing Huan, Klaus Olgaard
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 9-18
4. Pathogenesis of secondary hyperparathyroidism and
parathyroid hyperplasia.
Eduardo Slatopolsky, Alex J. Brown, Adriana Dusso
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 19-29
5. The different effects of high phosphate levels in
chronic kidney disease.
Antonio Canalejo, Yolanda Almadén, Mariano Rodríguez
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 31-40
6. The impact of cardiovascular calcifications in chronic
kidney disease: novel pathomechanistic insights.
Markus Ketteler, Ralf Westenfeld, Vincent Brandenburg
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 41-49
7. Vascular calcification, cardiovascular risk and
arterial stiffness in haemodialysis patients.
Teresa Adragão
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 51-56
8. Serum markers of bone turnover in the diagnosis of
renal osteodystrophy.
Aníbal Ferreira
Rev Port Nefrol Hipert 2005; 19 (4): 241-299
9. Role of vitamin D metabolites in the regulation of PTH
synthesis and secretion in chronic kidney disease.
Justin Silver, Iddo Z. Ben Dov
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 73-80
10. Vitamin D analogs for the management of secondary
hyperparathyroidism.
Kevin J. Martin, Esther A. González
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 81-86
11. Paracalcitol therapy for secondary
hyperparathyroidism.
Myles Wolf, Ravi Thadhani
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 87-96
12. Why target the parathyroid calcium-sensing receptor
for the treatment of secondary hyperparathyroidism?
Pablo Ureña Torres, Dominique Prié, Laurent Beck, Gérard
Friedlander
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 97-108
13. How are calcimimetics influencing our management of
uraemic hyperparathyroidism?
Simon J. Steddon, John Cunningham
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 109-115
14. Sevelamer Hydrochloride: A new Approach to
Hyperphosphatemia and Beneficial Effects Beyond Phosphate
Control
João M. Frazão, Patrícia Martins, Carla Santos-Araújo
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 117-124
15. Lanthanum carbonate: a new potent non-calcaemic
phosphate binder.
Fouad Albaaj, Alastair J. Hutchison
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 125-133
|
